Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) |
| |
| Authors: | Eyal C. Attar Philip C. Amrein James W. Fraser Amir T. Fathi Steven McAfee Martha Wadleigh Daniel J. DeAngelo David P. Steensma Richard M. Stone Julia Foster Donna Neuberg Karen K. Ballen |
| |
| Affiliation: | 1. Center for Leukemia, Massachusetts General Hospital Cancer Center, Boston, MA, USA;2. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA;3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA |
| |
| Abstract: | We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1–21 in 28 day cycles for up to 9 cycles. 23 patients (14 MDS/CMML, 9 AML) were enrolled. The maximally tested dose of bortezomib, 1.3 mg/m2, was tolerable in this regimen. Responses were seen in patients with MDS and AML. Further testing of this regimen is planned. |
| |
| Keywords: | Bortezomib and lenalidomide in MDS and AML |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
